A 28-year-old woman presents with fever, petechiae, and gum bleeding for 5 days. CBC shows WBC 85,000/μL with 70% blasts, Hb 6.2 g/dL, and platelets 15,000/μL. Bone marrow aspirate confirms acute myeloid leukemia (AML) with t(15;17). Coagulation studies show PT 18 s, aPTT 52 s, fibrinogen 80 mg/dL, and D-dimer markedly elevated. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context: APL with DIC This patient has **acute promyelocytic leukemia (APL)** — a medical emergency characterized by: - t(15;17) translocation (pathognomonic) - Severe coagulopathy with disseminated intravascular coagulation (DIC) - High early mortality if not managed correctly ## Why ATRA + ATO is the Correct Next Step **Key Point:** APL is the only acute leukemia where targeted therapy (ATRA + ATO) is superior to conventional chemotherapy and must be initiated immediately alongside supportive care. **High-Yield:** The t(15;17) fusion protein (PML-RARA) is exquisitely sensitive to ATRA and arsenic. These agents induce differentiation and degradation of the fusion protein, leading to remission in >90% of patients. **Clinical Pearl:** DIC in APL is driven by release of tissue factor and cancer procoagulant from abnormal promyelocytes. ATRA + ATO addresses the underlying leukemia while aggressive supportive transfusion therapy (FFP, cryoprecipitate, platelets) controls the coagulopathy. ### Management Algorithm for APL with DIC ```mermaid flowchart TD A[APL suspected: t(15;17) confirmed]:::outcome --> B{Coagulopathy present?}:::decision B -->|Yes| C[Start ATRA + ATO immediately]:::action B -->|No| C C --> D[Aggressive transfusion support]:::action D --> E[FFP + cryoprecipitate + platelets]:::action E --> F[Monitor PT/aPTT/fibrinogen q6-12h]:::action F --> G[Differentiation syndrome watch]:::urgent G --> H[Remission achieved in >90%]:::outcome ``` **Mnemonic:** **APL = ATRA + ATO** (not conventional chemo first) ### Why NOT Conventional Chemotherapy First? | Feature | ATRA + ATO | High-Dose Chemo | |---------|-----------|------------------| | Remission rate | >90% | ~80% | | Early death (DIC) | Lower | Higher | | Differentiation syndrome | Manageable | N/A | | Time to response | Days–weeks | Weeks | | Mechanism | Targets PML-RARA fusion | Cytotoxic | **Warning:** Conventional chemotherapy can worsen DIC and increase early mortality in APL. ATRA + ATO is now standard of care and must not be delayed. ## Supportive Care Priorities 1. **Transfusion thresholds:** Keep platelets >30,000/μL (not 10,000/μL) during induction 2. **FFP and cryoprecipitate:** Maintain fibrinogen >100 mg/dL 3. **Avoid diuretics and NSAIDs** — worsen DIC 4. **Monitor for differentiation syndrome** — fever, pulmonary infiltrates, renal dysfunction (days 5–21 of ATRA) [cite:Robbins 10e Ch 13]